Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
26 Items
Title  Creator  Group name  Publishing year 
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer Tarantino et al. EquipeCTCS 2023-08
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation Frenel et al. EquipeCTCS 2023-06
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort Bringuier et al. EquipeCTCS 2022-02
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial Dent et al. EquipeCTCS 2021-02
Evolution of overall survival and receipt of new therapies by subtype among 20?446 metastatic breast cancer patients in the 2008-2017 ESME cohort Grinda et al. EquipeCTCS 2021-06
ERR? promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors Vargas et al. EquipeCTCS 02 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database Gougis et al. EquipeCTCS Oct 19, 2019
Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapy Taourel et al. EquipeAP Dec 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients Jacquet et al. EquipeCTCS May 2018
Breast cancer and screening in persons with an intellectual disability living in institutions in France Trétarre et al. EquipeCTCS 03 2017
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study Delaloge et al. EquipeCTCS 09/2016
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study Jacot et al. EquipePC Mar 30 2016
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study Dell'Ova et al. EquipeCTCS 2015
Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations? Jacot et al. EquipeCTCS 2015
Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study Gligorov et al. EquipeCTCS Aug 2015
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study Bonnefoi et al. EquipeCTCS Feb 2015
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers Jacot et al. EquipeCTCS 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) Gourgou-Bourgade et al. EquipeCTCS Dec 2015
[Weakening osteopathies, chronic kidney disease, malabsorption, biological anomalies of calium/phosphorus metabolism: appropriate indications for a reasoned reimbursment of serum vitamin D measurement] Souberbielle et al. EquipeCTCS Jul-Aug 2014
[Vitamin D and breast cancer: physiopathology, biological and clinical implications] Firmin et al. EquipeCTCS Mar 2014
[HAS report on vitamin D measurement: don't go from an extreme situation to another as extreme situation] Souberbielle et al. EquipeCTCS Jan 2014
Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer El Demery et al. EquipeCTCS 2014
Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer Saadoun et al. EquipeCTCS Feb 2014
Iron homeostasis and anemia markers in early breast cancer Lamy et al. EquipeCTCS Jul 1 2014
Age and stage at diagnosis: a hospital series of 11 women with intellectual disability and breast carcinoma Satge et al. EquipeCTCS 2014
12>>>
26 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés